C-Bridge Capital Leads $150M Round In Merged Chinese Drug Developer

Login to View

C-Bridge Capital, a US$700 million-under-management healthcare private equity fund in China, has teamed up with Tianjin-based traditional Chinese medicine company Tasly Holding Group to invested US$150 million in a newly created Chinese drug developer resulted from a merger of two pharmaceutical firms.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in